Selecting a decision model for economic evaluation: A case study and review

被引:55
作者
Karnon J. [1 ]
Brown J. [1 ]
机构
[1] Health Economics Research Group, Brunel University, Uxbridge
基金
英国医学研究理事会;
关键词
Breast Cancer; Decision Tree; Adjuvant Therapy; Economic Evaluation; Discrete Event Simulation;
D O I
10.1023/A:1019090401655
中图分类号
学科分类号
摘要
The increased use of modelling techniques as a methodological tool in the economic evaluation of health care technologies has, in the main, been limited to two approaches - decision trees and Markov chain models. The former are suited to modelling simple scenarios that occur over a short time period, whilst Markov chain models allow longer time periods to be modelled, in continuous time, where the timing of an event is uncertain. In the context of economic evaluation, a less well developed technique is discrete event simulation, which may allow even greater flexibility. Taking the economic evaluation of adjuvant therapies for breast cancer as an illustrative example, the process of building a decision tree, a Markov chain model, and a discrete event simulation model are described. The potential benefits and problems of each approach are discussed. The suitability of the modelling techniques to economic evaluations of health care programmes in general is then discussed. This section aims to illustrate the areas in which the alternative modelling methods may be most appropriately employed. © Baltzer Science Publishers BV.
引用
收藏
页码:133 / 140
页数:7
相关论文
共 21 条
[1]  
Buxton M.J., Health economics in the 1990's, Health Economics of Depression (1st Ed.), pp. 1-13, (1993)
[2]  
Blumenschein K., Johannesson M., Economic evaluation in healthcare, Pharmacoeconomics, 10, 2, pp. 114-122, (1996)
[3]  
Buxton M.J., Et al., Modelling in economic evaluation: An unavoidable fact of life, Health Economics, 6, 3, pp. 217-227, (1997)
[4]  
Bloom B., Buxton M., Drummond M., Luce B., Sheldon T., The pros and cons of modelling in economic evaluation, OHE Briefing, 33, pp. 1-12, (1997)
[5]  
Fletcher J., Hicks N.R., Kay J.D.S., Boyd P.A., Using decision analysis to compare policies for antenatal screening for Down's syndrome, British Medical Journal, 311, pp. 351-357, (1995)
[6]  
Lieu T.A., Watson S.E., Washington A.E., The cost-effectiveness of prenatal carrier screening for cystic fibrosis, Obstetrics and Gynaecology, 84, 6, pp. 903-912, (1994)
[7]  
Revicki D.A., Et al., Modelling the cost effectiveness of antidepressant treatment in primary care, Pharmacoeconomics, 8, 6, pp. 524-540, (1995)
[8]  
Briggs A.H., Sculpher M.J., Logan R.P., Aldous J., Ramsay M.E., Baron J.H., Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age, British Medical Journal, 312, 7042, pp. 1321-1325, (1996)
[9]  
Davies A., Cuninghame K., Breast Cancer: Screening and Treatment, (1992)
[10]  
Fox K.R., Adjuvant therapies for node-positive operable breast cancer, Breast Cancer Treatment - A Comprehensive Guide to Management (1st Ed.), pp. 265-289, (1991)